Total amount: € 0,00
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
Online ISSN 1827-1839
Aleš BLINC 1, 2, Matija KOZAK 1, 2, Mišo ŠABOVIČ 1, 2, Mojca BOŽIČ MIJOVSKI 1, 3, Mojca STEGNAR 1, 3, Pavel POREDOŠ 1, 2, Andrej KRAVOS 4, Breda BARBIČ-ŽAGAR 5, Janez STARE 6 , Maja POHAR PERME 6
1 Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia; 2 Faculty of Medicine, University of Ljubljana, Slovenia; 3 Faculty of Pharmacy, University of Ljubljana, Slovenia; 4 Department of Family Medicine, Faculty of Medicine, University of Maribor, Slovenia; 5 Krka, d. d., Novo Mesto, Slovenia; 6 Institute of Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, Slovenia
BACKGROUND: Patients with peripheral arterial disease (PAD) are at very high risk for cardiovascular events. How do patients with PAD differ from age- and sex-matched controls in survival, major ischemic events and revascularization procedures when both groups were managed according to the European guidelines on cardiovascular disease prevention?
METHODS: 742 patients with PAD and 713 age and sex-matched control subjects without PAD, both groups aged 65±9 years at inclusion, were managed for 5 years according to the European guidelines on cardiovascular disease prevention and evaluated yearly for occurrence of death, non-fatal major ischemic events and revascularization procedures (minor events).
RESULTS: In the PAD group, the 5-year survival was 84.7% (CI 82.1 – 87.3%) vs. 93.3% (CI 91.5 – 95.2%) in the control group, p<0.001. In the PAD group the proportion of cardio-vascular deaths did not differ significantly from non-cardio-vascular deaths (6.9 vs. 8.4%, p = 0.14), while in the control group cardio-vascular deaths were less frequent (2.4 vs. 4.3 %, p = 0.05). The groups differed in 5-year major event-free survival: 76.7% (CI 73.7–79.8%) in PAD vs. 89.9% (CI 87.7 –92.2%) in controls, p<0.001, and in event-free survival: 56.2% (CI 52.7 – 59.9%) in PAD vs. 82.4% (CI 79.9-85.3%) in controls, p<0.001.
CONCLUSIONS: Patients with PAD had a higher risk of all-cause death, major and minor non- fatal cardiovascular events compared to control subjects. In our group, cardiovascular events were not the leading cause of death in patients with PAD. (ClinicalTrials.gov number NCT00761969.)